Mahidol University Annual Research Abstracts, Vol.28, 2001
101
ogy, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; 3Department of Infectious Diseases, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
Key words : IL-16 gene; polymorphism; HIV-1
Interleukin 16 (IL-16) is a chemotactic cytokine which binds to CD4 and addects T cell activation. Here we report a novel single nucleotide polymorphism, T to C, in the promoter region of the IL-16 gene in two distinct Asian polulations, Japanese and Thai. This mutation occurs at an allele frequency of approximately 22% and 18%, respectively. Although IL-16 potently suppresses replication of human immunodeficiency virus type 1 (HIV-1), we observed no significant difference in the allele frequency of this polymorphism between HIV-1-infected and non-HIV-1-infected individuals in both Asian populations. Since differential IL-16 levels have been reported to be associated with inflammatory diseases such as systemic lupus erythematosus, atopic dermatitis and allergic asthma, it would be of interest to analyze the allele frequency of this mutation in patients with these autoimmune and allergic diseases.
(Genes and Immunity 2000; 1:293-4.Supported by Japanese Foundation for AIDS Prevention)
IMMUNOGENICITY AND ADVERSE REACTION OF INFLUENZA VACCINATION
IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASES
(NO. 260)
Chantapong Wasi1, Uraiwan Kositanont1, Raweewan Kunyok1, Sontana Siritantikorn1, Phunsup Wongsurakiat2, Tasneeya Suthamsmai2, Nanta Maranetr2, Prasert Thongchareon1
1Departments of Microbiology, 2Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
Key words : Influenza vaccination, Immunogenicity, Chronic Obstructive Pulmonary Diseases
Background : Worldwide influenza outbreaks occur every year. In the elderly and patients with chronic illness, influenza attacks often lead to severe complication and death. Split influenza vaccines have been available in Thailand since 1996. We therefore conduct the prospective longitudinal study in COPD patients attend the clinic at Siriraj Hospital to study the efficacy and cost-effectiveness of influenza vaccination.
Objectives : To study the antibody response to the influenza A (H3N2), A (H1N1) and B after the first and second doses, follow up the antibody levels and study the adverse reactions after vaccination.
Subjects and Vaccines : The vaccinees were patients with COPD who attend COPD clinic at Siriraj Hospital regularly. The 114 patients were recruited in June 1997. The vaccine was the purified trivalent split-virus vaccine manufactured by Pasteur Merieux, Lyon-France. Each dose (0.5 ml) of vaccine used in 1997-1998, contained influenza A/Texas/36/91 (H1N1), A/Nanchang/933/95 (H3N2) and B/Harbin/7/94.
Methods : The recruited patients were randomized given either 0.5 ml. Of influenza vaccine subcutaneous for the first dose and four weeks apart for the second dose, or vitamin B1 as placebo. Blood were collected at the first day of injection, at 4, 8 weeks, 6 months and at one year. Hemagglutination-inhibition test was performed, using the flu A (H1N1), A (H3N2) and B viruses prepared for vaccine components as the antigens.
Results : The antibody response shown by fourfold rising of antibody titers of influenza A (H3N2) and A (H1N1) were high; but not for influenza B.Antibody response after first vaccination showed high seroconversion rate and high titers which should be enough for protection (33 40). In those with high antibody before vaccination, the titers were significantly increased after first dose but not increased after second dose. The antibody level did not decline after six months and one year. Adverse reaction were reported by 31/57 (49%) of vaccine group and 29/57 (44%) of placebo group. The vaccinated subjects had significantly more local reaction (swelling and itching) than placebo group. All reported adverse reaction were mild and self limited.
Conclusion : The antibody response to flu A (H3N2) and A (H1N1) in COPD patients is satisfactory and should not different from the general population of old age group. Influenza B elicit low antibody response. In elderly with no previous vaccination, one dose of influenza vaccine showed high immunogenicity. The second dose did not enhance the antibody response.The adverse reaction is mild, tolerated and self-limited.
(Presented at International Conference on New Vaccines and Antiviral Drugs November 25-27, 2000, Ayutthaya, Thailand.)
MOLECULAR EPIDEMIOLOGY OF HIV-1 IN THAILAND: 1993-1998 (NO. 261)
Ruengpung Sutthent1, Piyanot Wirachsilp1, Thayathep Phiroonlaong1, Kwonchit Samransurp1, Panita Pratheepawanich2, Kulkanya Chokpaibulkit3, Pongsakdi Chaisilwatana4, Somsith Tunsupasawasdikul5, Surapol Kaoriangudom6, Paijit Warachit7, Mitsuo Honda8
Departments of Microbiology1, Pediatric3, Obstertric-Gynecology4, Faculty of Medicine Siriraj Hospital, Mahidol University, Lampang Hospital2, Bamrasnaradura Hospital5, Division of AIDS6, National Institute of Health7, Ministry of Public Health, Thailand, Department of Communicable Disease Control, National of Infectious Diseases Japan8
Key words: Molecular epidemiology, HIV-1, Thailand
HIV-1 nucleotide sequences were analyzed from 141 samples collected in year 1993 and 1998 from children with vertical transmission (n=40); heterosexual (n=68); and injecting drug user (n=33). DNA lysate from peripheral blood mononuclear cells PBMCs was used as template to amplify HIV-1env (C2-V3) and pol (RT) genes for nucleotide sequencing analysis. The nucleotide sequence data was analysed by DNASIS and phylogenetic analysis was performed using software DNASTAR and PAUP. All 141 HIV-1 isolates were identified as subtype E by V3 nucleotide sequence analysis. Glutamic acid (Q) in V3 motif of subtype E (GPGQ) was changed to R, H, K, or L about 70% (89/128), 50% (11/21), and 40%(6/15) in HIV-1 isolates from heterosexual, IDU, and vertical transmission risk groups, respectively. Methionine (M) was found to replace I at amino acid position 12 in V3 region about 23% (30/128), 28% (6/21), and 33% (5/15) in HIV-1 isolates from hetero-
0 responses so far ↓
There are no comments yet...Kick things off by filling out the form below.
Leave a Comment